Serplulimab
Total Neoadjuvant Therapy
Tao Zhangmonoclonal_antibodyPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
3 Active assets in the Total Neoadjuvant Therapy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin Tao Zhang | Phase 3 | B |
Capecitabine Tao Zhang | Phase 3 | B |
Toripalimab Ruijin Hospital | Phase 2 | CCC |
Same molecule, other indications
Serplulimab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →